Display options
Cite
Booth RF, Manley PW, Buckham SP, et al. 5-[6-1 -(Cyclohexyl-1 H-tetrazol-5-YL)hexyl]-1,8-naphthyridin-2-(1H)-one, SC-44368, a Potent Anti-aggregatory Agent which Selectively Inhibits Platelet Cyclic AMP Phosphodiesterase. Platelets. 1992;3(3):129-36doi: 10.3109/09537109209013173.
Booth, R. F., Manley, P. W., Buckham, S. P., Hassall, D. G., Honey, A. C., Lad, N., Lunt, D. O., Oswald, S., Porter, R. A., & Tuffin, D. P. (1992). 5-[6-1 -(Cyclohexyl-1 H-tetrazol-5-YL)hexyl]-1,8-naphthyridin-2-(1H)-one, SC-44368, a Potent Anti-aggregatory Agent which Selectively Inhibits Platelet Cyclic AMP Phosphodiesterase. Platelets, 3(3), 129-36. https://doi.org/10.3109/09537109209013173
Booth, R F, et al. "5-[6-1 -(Cyclohexyl-1 H-tetrazol-5-YL)hexyl]-1,8-naphthyridin-2-(1H)-one, SC-44368, a Potent Anti-aggregatory Agent which Selectively Inhibits Platelet Cyclic AMP Phosphodiesterase." Platelets vol. 3,3 (1992): 129-36. doi: https://doi.org/10.3109/09537109209013173
Booth RF, Manley PW, Buckham SP, Hassall DG, Honey AC, Lad N, Lunt DO, Oswald S, Porter RA, Tuffin DP. 5-[6-1 -(Cyclohexyl-1 H-tetrazol-5-YL)hexyl]-1,8-naphthyridin-2-(1H)-one, SC-44368, a Potent Anti-aggregatory Agent which Selectively Inhibits Platelet Cyclic AMP Phosphodiesterase. Platelets. 1992;3(3):129-36. doi: 10.3109/09537109209013173. PMID: 21043905.
Copy Download .nbib Format: NLM
Share it on

Platelets. 1992;3(3):129-36. doi: 10.3109/09537109209013173.

5-[6-1 -(Cyclohexyl-1 H-tetrazol-5-YL)hexyl]-1,8-naphthyridin-2-(1H)-one, SC-44368, a Potent Anti-aggregatory Agent which Selectively Inhibits Platelet Cyclic AMP Phosphodiesterase.

Platelets

R F Booth, P W Manley, S P Buckham, D G Hassall, A C Honey, N Lad, D O Lunt, S Oswald, R A Porter, D P Tuffin

Affiliations

  1. Departments of Biology and Chemistry, Searle Research and Development, Division of G. D. Searle & Co Ltd., Lane End Road, High Wycombe, Buckinghamshire, HP12 4HL, UK.

PMID: 21043905 DOI: 10.3109/09537109209013173

Abstract

SC-44368 (5-[6-(1-cyclohexyl-1H-tetrazol-5-y)hexyl]-1,8-naphthyridin-2(1H)-one) is a potent and selective competitive inhibitor of platelet cyclic AMP-dependent phosphodiesterase (cAMP-PDE) (Ki: 1.65 μM). For the phosphodiesterase isoenzyms from human platelets SC-44368 shows a 26-fold selectivity (IC50 ratio) for the inhibition of the cAMP-PDE over the cyclic GMP-dependent phosphodiesterase (cGMP-PDE). By comparison, 3-isobutyl-1-methyl-xanthine (IBMX) inhibited the cAMP-PDE and cGMP-PDE from human platelets with approximately equal efficacy. Broad inhibitory activity was evident against human platelet aggregatory responses in vitro. IC50 values of 18.1 ± 5.3 μM (25 nM platelet activating factor, PAF), 17.3 ± 3.0 μM (1.0 μg/ml collagen) and 24.2 ± 10.3 μM (1μM ADP) were obtained against maximum increases in platelet-rich plasma (PRP) light transmission achieved by each agonist. SC-44368 potentiated the prostacyclin-induced increase of intra-platelet cAMP levels but did not potentiate the sodium nitroprusside-induced increase of intraplatelet cGMP levels. In an ex vivo model of platelet aggregation SC-44368 (3 mg/kg, i.v.) produced a potent inhibition of collagen-induced platelet aggregation. SC-44368 produced only weak hypotensive activity in the rat. Thus, SC-44368 is a novel cAMP-PDE inhibitor which possesses potent, broad spectrum anti-aggregatory properties.

Publication Types